LIA
PGNX

LS Investment Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

LS Investment Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,272
Closed -$9K – 1745
2020
Q1 		$9K Hold
2,272
– – ﹤0.01% 1570
2019
Q4 		$12K Hold
2,272
– – ﹤0.01% 1639
2019
Q3 		$11K Hold
2,272
– – ﹤0.01% 1635
2019
Q2 		$14K Hold
2,272
– – ﹤0.01% 1599
2019
Q1 		$11K Hold
2,272
– – ﹤0.01% 1614
2018
Q4 		$10K Hold
2,272
– – ﹤0.01% 1621
2018
Q3 		$14K Hold
2,272
– – ﹤0.01% 1667
2018
Q2 		$18K Hold
2,272
– – ﹤0.01% 1612
2018
Q1 		$17K Hold
2,272
– – ﹤0.01% 1615
2017
Q4 		$14K Sell
2,272
-20,534
-90% -$125K ﹤0.01% 1640
2017
Q3 		$168K Buy
22,806
+5,909
+35% +$37.5K 0.01% 1003
2017
Q2 		$115K Buy
16,897
+13,952
+474% +$103K 0.01% 1093
2017
Q1 		$28K Buy
+2,945
New +$29.4K ﹤0.01% 1499

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

LS Investment Advisors's PGNX Position: Q2 2020 in Review

LS Investment Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 2,272 shares — an estimated $9K sold.

LS Investment Advisors first reported a position in PGNX in Q1 2017 and held it in 13 quarters. The position peaked at $168K in Q3 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • LS Investment Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • LS Investment Advisors sold 2,272 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $9K.
  • LS Investment Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 13 quarters.
  • LS Investment Advisors's Progenics Pharmaceuticals Inc position peaked at $168K in Q3 2017.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on LS Investment Advisors's 13F filing for Q2 2020, filed 10 Aug 2020.